Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Disease-free survival
Esophageal cancer
Gastroesophageal junction cancer
Meta-analysis
Overall survival
Surrogacy
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
29
11
2021
revised:
11
04
2022
accepted:
16
04
2022
pubmed:
24
5
2022
medline:
29
6
2022
entrez:
23
5
2022
Statut:
ppublish
Résumé
To evaluate disease-free survival (DFS) as a surrogate endpoint for overall survival (OS) using aggregate-level data from resectable esophageal or gastroesophageal junction cancer (EC/GEJC) trials assessing therapies in (neo)adjuvant and perioperative settings. A systematic literature review was conducted to identify trials reporting OS and DFS, or compatible progression-free survival (PFS). Bivariate random-effects meta-analysis was used to estimate correlation between the treatment effects on DFS/PFS and OS, and weighted linear regression models assuming trial sample sizes as weights were used to estimate surrogacy equations. The primary analysis consisted of trials across all treatment settings, and secondary analysis consisted of trials only in the adjuvant setting. Leave-one-out cross-validation (LOOCV) was performed to measure the stability and predictive accuracy of the surrogacy equations while surrogate threshold effects (STE)-the minimum treatment effect on DFS/PFS that would translate into a positive OS benefit-were derived to measure their usefulness. The primary analysis included 26 trials. The estimated correlation coefficient between the hazard ratio (HR) of DFS/PFS (HR Our meta-analysis suggests that HR
Identifiants
pubmed: 35605522
pii: S0959-8049(22)00237-4
doi: 10.1016/j.ejca.2022.04.027
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-130Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement The authors declare the following financial interests/personal relationships that may be considered as potential competing interests: J.A.A. is an ad hoc advisor to Bristol Myers Squibb and his institution has also received research grants from Bristol Myers Squibb. P.S., M.K., and I.K. report employment by Bristol Myers Squibb. M.P. and L.L. report employment, and S.K. reports contract, by Evidinno Outcomes Research Inc., which was commissioned by Bristol Myers Squibb to conduct this study. Authors report no other conflicts of interest.